We would love to hear your thoughts about our site and services, please take our survey here.
Yes l noticed that too. I was wondering if they are going to compete directly with ITM or are they only making some of the components necessary for the PEM process? Either way I suppose JMs involvement is likely to boost the UK hydrogen industry on the whole
The inews article is interesting in my opinion. A section states:
- The central case, seen as the most likely, would see
the steady state reached between 2023 and 2024,
with Covid-19 adding to winter pressures for the
next two years, but not throughout the rest of the
year -
I also think that this scenario is most likely and will give Novacyt decent revenue from Covid products for at least a year. Shares are worth buying at the current price and holding in my opinion.
Big buying opportunity in my opinion. Remember the capacity in Madagascar alone has increased from 3000 to 12,000tpa since the September commissioning of the new Vatomina module. It is planned to rise again to approx 30,000tpa in H1 2022. The downstream processing in India and Mozambique potential is in addition to this. I have topped up at 84p this afternoon. Very happy.
Excellent video. Thanks for sharing
They could do with getting production going at 9,000 tpa facility at Vatomina. This should have a significant effect on revenue.
I have got my eyes open and the Results look OK to me. $440m in cash, to a market cap of £955. Seems alright ....
Their 3 founded entities which are now being publicly traded are worth over $5.4bn. Puretech still own between 9% and 19% of these companies, so this could be worth well over $400m by my rough calculation.
Also, as per Daphne Zohar, Founder and Chief Executive Officer of PureTech - "In addition to our equity holdings across all of our Founded Entities, we are also due royalties on potential product sales from Gelesis, Karuna and Follica. Royalties due to us from each of those programs could potentially be worth as much as - or more than - our equity in each program, depending on the extent of future product sales."
In my view it will take a few years for the royalties to flow in but the situation is very promising.
Personally I don't think that PureTech's Wholly Owned Programs have been fully factored into the share price, as these are approved they should have a significant effect. However, the companies cash pile may be reduced in the medium-term as these programs are developed. PureTech's Operating Loss for the period was $68.1 million (June 30, 2020: 52.8 million).
Long-term hold for me. The markets seem to dwell on the fact that they make an operating loss and cash does not fall into free cash flow; rather than focussing on long-term potential.
Seems like a good deal to me. £6m for approx 12 million tons of flake graphite which is selling for between $700 and $1000. If I understand CEO Shishir Poddar correctly in todays Proactive interview, the first 50,000TPA processing module at Montepuez could be up and running next year.
I understand that the company will undergo significant expenses commissioning the sites and excavating/processing the ore, plus there are obvious geopolitical risks. However the potential revenue here is huge.
They are also of course developing their downstream processing activities.
Another great RNS.
TGR have achieved a huge amount this year. The mining operation should be producing over 30,000 TPA next year from the 2 mines in Madagascar. Up from 3000 at the start of this year.
The downstream specialist materials arm is developing so fast it is hard to keep up. The sectors that they can work with have huge potential (aerospace, automotive, biomedical, renewable energy etc) - particularly batteries.
The company should also hopefully start making a profit next year which will obviously take the interest of many investors and analysts. I am happy for the SP to stay subdued this year whilst I accumulate. Honestly one of the most exiting opportunities I have seen for a while.
Am I correct in my understanding that San Leon are charging 17% (seventeen!) Interest on the monies owed to them?. .
It is not good that the payment has been delayed but that is some compensation. I seem to remember that Midwestern have delayed payments in the past but have honoured them eventually. The oil price has risen this year and demand should increase as we come out of lockdown so things in the medium term look promising in my opinion.
My_Way. Thanks for a very informative piece. I feel that there is still decent revenue to be had from PCR testing, particularly from our capacity to distinguish recent variants. However, l agree that it is the fast and successful development of a working LAMP test which will propell Novacyt's SP further.
Regarding PR. Yesterday was a major result for Surescreen and their LFT offerings, and today a decent bit of exposure for the VMD LAMP product.
For Novacyt and their low profile PR , there are 2 scenarios that spring to mind for me. Either they are very well advanced with their LAMP product development and feel that when introduced its qualities will almost sell itself; OR the product development is behind schedule and they are understandably being low key about it.
I hope and expect it is the former scenario, as l feel LAMP could be a very important part of the testing picture going forward. I did take a bit of profit last month but continue to hold the majority of my Novacyt shares. They have shown themselves to be an innovative and resourceful company so far.
Interesting article in The Times today. It mentions a lamp test being developed by VMD Health. Possibly mass produced by the summer. The race is on...
Some of the article below:
... The be.well test uses Lamp technology — loop-mediated isothermal amplification — to search for fragments of the virus’s genetic material. Without the need for cycles of heating and cooling used by standard tests, results come back within an hour. While other types of Lamp tests rely on portable laboratories to process samples, the be.well device plugs a nasal swab into a cartridge the size of a hard disk. Manufacturers say that it can be mass produced, allowing the test to be widely used.
Buy & hold. Another massive dividend coming later in the year.
Yes. LOTS of coverage on BBC about this now. Definitely PCR. It would be great for the company if Novacyt were involved. Especially if they could make it public.
I found this article on the Manaus P1 variant interesting and worrying in equal measures. Too early to know how this will pan out, but for sure I reckon the world will need the best testing resources for a long while yet to identify and control any variants which do threaten us.
https://www.sciencemag.org/news/2021/01/new-coronavirus-variants-could-cause-more-reinfections-require-updated-vaccines
I saw a feature on BBC TV News about this today. They gave it some good airtime, had a reporter in Germany and showed video of the 'box'.
My point is that with the resources at their disposal, why can't Novacyt PR get airtime like this to explain the features and benefits of their fast, accurate, non-lab products.
Yes. I revisited an interview with CEO Paul Kerr on Proactive Investors from May 20. Just after the last fundraise. Although, in my opinion, his presentation style is quite hesitant, he was very clear regarding their view that the Fusion platform is amongst the market leaders and has an important role to play in the Covid crisis. Their "chance to shine".
I confess that I don't know much about the technicalities of what they do, and it is possible that they will fail, but if their platforms do make a significant contribution in creating Covid busting antibodies, the company sp could fly. Massive onward opportunities to use the platform to develop other drug candidates.
I wonder if IKA's research relationship with Toyota is not particularly active at the moment. They have not been mentioned much lately in RNS's that I have seen. However, The IKA 2020 annual report states
..... Building Ilika’s intellectual property portfolio in solid state batteries has
continued to be a focus this year. Ilika believes its patents ring-fence and
protect critical IP to avoid competitors working around a single patent. Ilika
now maintains a portfolio of 15 patent families in solid state batteries, of
which three are jointly owned with Toyota. This portfolio includes 20
granted patents.....
Hopefully some of these patents will be worth something. It may take a LOT of legal wrangling to get a decent return though.
IKA do have some ongoing UK projects with Honda, Ricardo, McLaren & Jaguar Land Rover. Although these look interesting, and the companies partaking are big names in automotive, I do worry that it is all pretty small scale (£5.1m grant funding), and looking at niche issues rather than large scale projects for Solid State batteries for vehicles.
I do worry that we may get left behind by some of the huge global projects ongoing at the moment.
Many thanks. Very interesting. I note he says the LFT test is "very very much less sensitive" than PCR. And "Indeed it even failed to detect two out of five samples with the highest level of viral gene copies, these displayed a PCR CT of < 20".
My view is that regarding mass testing, I suppose that they may have some use weeding out some people with high viral loads testing positive. However I am concerned that many people who have a 'negative' LF test may think ,and subsequently behave like, that they are definitely not infected when this may not be the case. Regarding sending them to care homes to test visitors.... that is lunacy, 50/50 chance of success...........
Prof Richard Tedder, Senior Research Investigator in Medical Virology, Imperial College London, said:
“The data presented on the performance of the Innova lateral flow assay for detecting SARS-CoV-2 clearly indicate in this study that when compared against a benchmark molecular test such as a quantitative PCR the lateral flow test is very very much less sensitive, detecting only about half of the known positive samples subjected to testing. Indeed it even failed to detect two out of five samples with the highest level of viral gene copies, these displayed a PCR CT of < 20 (i.e. were samples which could be diluted one million fold and still give a positive PCR signal). This graphically shows that this assay is simply not sensitive enough to use to test persons with a view to confirming an absence of infection and thereby an absence of infectivity. A negative result with this lateral flow test simply does not infer an absence of infection.”
There is an article in today's Times entitled:
Doubts about family reunions as fast tests miss half of infections
Some of the content includes:
... Care homes have been told that lateral flow tests are not accurate enough for allowing visitors in after data from a pilot showed that they missed 51 per cent of coronavirus cases. Figures published yesterday by the Scientific Advisory Group for Emergencies (Sage) dealt a blow to Boris Johnson’s hopes of using rapid tests to allow people more freedom....
Can anyone please provide a link to where I can view these SAGE figures?.
If accurate, they may provide further evidence of major issues with these devices.